CKMT1A is a novel potential prognostic biomarker in patients with endometrial cancer
Fig 7
The expression of CKMT1A in association with the clinical characteristics and overall survival (OS) of patients with endometrial cancer.
(A) The mRNA expression levels of CKMT1A in different groups of FIGO stages are displayed (****, P<0.0001). (B) Impact of CKMT1A expression on overall survival in clinical patients (n = 39).